IDSOMICS

## Meet the team

## A cancer and stem cell biologist



## **Floris Foijer** PhD, Professor & CSO

Following his PhD training on cell cycle regulation with Prof. Hein te Riele at the Netherlands Cancer Institute (2000–2006), Floris continued his training at Harvard

Medical School (2007–2009) under Prof. Peter Sorger as a Dutch Cancer Society fellow, and at the Wellcome Trust Sanger Institute (2009–2011) with Prof. Allan Bradley as an EMBO fellow.

During this period, Floris developed in vivo models to better understand how genomic instability promotes cancer and contributes to cancer cell evolution.

In 2011, Floris joined the newly established European Research Institute for the Biology of Ageing (ERIBA) at the University Medical Center Groningen (UMCG) to start a research group focused on how genomic instability drives cancer.

Together with the lab of **Peter Lansdorp**, he developed a platform to **quantify** chromosome copy number changes in single cells (single-cell genomics, scWGS), and with Maria Colomé-Tatché, created the AneuFinder software to analyze scWGS data.

Their platform has become a **standard in the field** and has significantly contributed to our understanding of how **genomic instability** and resulting **intra-tumor** heterogeneity drive cancer progression.

The lab currently focuses on:

<u>The role of genomic instability in cancer cell evolution</u>



- The immune response to genomically unstable cancers
- Targetable vulnerabilities of cancer cells

In 2016, Floris established a facility at ERIBA that generates induced pluripotent stem cells (iPSCs) and supports CRISPR/Cas9-mediated genome editing. Since its inception, the facility has supported more than 140 iPSC and CRISPR projects and generated over 120 iPSC lines for more than 60 research groups.

In 2018, he helped establish the **Research Sequencing Facility** at ERIBA to support advanced sequencing applications, including **scWGS**.

To ensure the long-term sustainability of these facilities, Floris co-founded **iPsomics** with Peter Ketelaar, where he currently serves as Chief Scientific Officer (CSO).

[Publications on PubMed] [Google Scholar profile]



©2025 - Form | All right reserved

